Results 101 – 110 of 231 for second dose AstraZeneca (0.04 seconds)

US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer

US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer

AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma

AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma

PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack

prevention of cardiovascular events AstraZeneca today announced details of a sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of ...

Results from the MIRACLE Phase III trial show treatment with Fasenra resulted in a statistically significant reduction of 74% in annual exacerbation rate in patients in Asia with severe eosinophilic asthma

AstraZeneca announced that results from the MIRACLE Phase III trial have been published in Respiratory Medicine demonstrating Fasenra (benralizumab) ...

AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress

AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress

Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome

First major US guideline to include expanded indication for Brilinta in patients with a heart attack beyond one year 31 March 2016 AstraZeneca today ...

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and ...

AstraZeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291

AstraZeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291

Airsupra (PT027) approved in the US for asthma

significant reduction compared to albuterol at the approved dose of 180mcg albuterol/160mcg budesonide.1 In DENALI, Airsupra significantly improved ...

PT027 recommended by FDA Advisory Committee as new rescue treatment for asthma

is a potential first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the US containing albuterol, a ...

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next